Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity.
Bisphosphonates are primarily known for their ability to inhibit osteoclast-mediated bone resorption. They are an indispensable part of therapy for patients with cancers that cause osteolysis. However, there is now a growing body of evidence from preclinical research showing that bisphosphonates also exhibit antitumor activity, both in vitro and in vivo. They can affect molecular mechanisms of tumor cell adhesion, invasion, and proliferation; reinforce the effects of cytotoxic agents in a synergistic manner; and exhibit antiangiogenic and immunomodulatory effects. These preclinical findings reveal exciting ways of optimizing bisphosphonate therapy in oncology to fully exploit their antitumor potential.
Clézardin
Philippe
P
Institut National de la Sante et de la Recherche Medicale Research Unit 664, Laennec School of Medicine, Lyon, France. clezardin@lyon.inserm.fr
Ebetino
Frank H
FH
Fournier
Pierrick G J
PG
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001859:Bone Neoplasms / Q000556:secondary; D001862:Bone Resorption / Q000188:drug therapy*; D045744:Cell Line, Tumor; D004164:Diphosphonates / Q000494:pharmacology*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents; D004164:Diphosphonates